Albuterol in Individuals With Late Onset Pompe Disease (LOPD)
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Albuterol is a drug approved by the US Food and Drug Administration (FDA) for treating
breathing problems such as asthma. Studies have shown that albuterol may be beneficial in
improving muscle function in people with late-onset Pompe disease. The purpose of this study
is to evaluate whether albuterol is safe and effective for improving muscle function in
people with late-onset Pompe disease, whether or not they are receiving enzyme replacement
therapy (ERT). For this study, albuterol is considered an investigational drug. The word
"investigational" means albuterol is not approved by the FDA for individuals with late-onset
Pompe disease.